Type I Interferon Production In White Blood Cells Regulated By A New Mechanism

Main Category: Immune System / Vaccines
Also Included In: Blood / Hematology;  Biology / Biochemistry;  Infectious Diseases / Bacteria / Viruses
Article Date: 13 Jan 2009 - 5:00 PST

email to a friend   printer friendly   view / write opinions   rate article

A study from a team of researchers led by Dr. Andrew P. Makrigiannis, Director of the Molecular Immunology Research Unit at the IRCM, has identified a new mechanism regulating interferon production. This discovery, co-authored by scientists from the International Medical Center of Japan (Tokyo), the National Cancer Institute at Frederick (Maryland) and the McGill Centre for the Study of Host Resistance, was published in the Journal of Experimental Medicine.

The plasmacytoid dendritic cell (pDC) is a type of white blood cell. The primary function of this cell type is to produce type I interferon when the body is infected by a virus. The pDC has special surface receptors that can detect many types of viruses. Type I interferon is thus very important for the clearance of a viral infection. "Working with mice, we have identified a mechanism that regulates the amount of interferon that is produced by pDCs, explains Dr. Makrigiannis. That mechanism is a protein-protein interaction between surface receptor Ly49Q and the class I major histocompatibility complex (MHC) molecule."

It is known that viruses often cause a decrease of class I MHC molecules on cells. The team of scientists believes that the reason for this may be to stop interferon production by the pDCs. Thus, class I MHC recognition by Ly49Q on pDCs is necessary for the optimal activation of innate immune responses in vivo.

The discovery of this molecular strategy will very likely have a great impact in virology, and could eventually help physicians develop better therapeutic strategies to fight the infectious diseases afflicting their patients.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

This work was supported by an operating grant from the Canadian Institutes of Health Research (CIHR). Lee-Hwa Tai is supported by a CIHR Cancer Training Program scholarship. Simon Bélanger is supported by a Fonds de la recherche en santé du Québec scholarship. Andrew P. Makrigiannis is supported by a New Investigator Award from the CIHR.

Reference: Tai LH, Goulet ML, Bélanger S, Toyama-Sorimachi N, Fodil-Cornu N, Vidal SM, Troke AD, McVicar DW, and Makrigiannis AP. (2008) Positive regulation of plasmacytoid dendritic cell function via Ly49Q recognition of class I MHC. J. Exp. Med., December 22; 205: 3187-3199.

The online version of this article is available at: http://jem.rupress.org/current.shtml#IN_THIS_ISSUE.

Dr. Andrew P. Makrigiannis is Director of the Molecular Immunology Research Unit at the IRCM. He is Associate Researcher in the Department of Medicine at the Université de Montréal and is also Associate Member in the Department of Microbiology and Immunology and in the Department of Medicine, Division of Experimental Medicine at McGill University.

Established in 1967, the IRCM (http://www.ircm.qc.ca) now has 35 research units specialized in areas as diverse as systems biology, immunity and viral infections, cardiovascular and metabolic diseases, cancer, medicinal chemistry, clinical research and ethics. It has a staff of more than 450 people. The IRCM is an independent institution, affiliated with the Université de Montréal and has built, over the years, a close collaboration with McGill University.

Information:

Andrew P. Makrigiannis, Ph.D.
Director of the Molecular Immunology Research Unit
http://www.ircm.qc.ca/

Lucette Thériault
Communications Director
http://www.ircm.qc.ca

Source: Andrew P. Makrigiannis
Institut de recherches cliniques de Montreal